Caparrós-Martín, Jose A.
Saladie, Montserrat
Agudelo-Romero, S. Patricia
Reen, F. Jerry
Ware, Robert S.
Sly, Peter D.
Stick, Stephen M.
O’Gara, Fergal
,
Funding for this research was provided by:
Health Research Board (HRB-ILP-POR-2019-004, HRB-ILP-POR-2019-004, HRB-ILP-POR-2019-004, HRB-ILP-POR-2019-004)
Irish Thoracic Society (MRCG-2018-16, MRCG-2018-16, MRCG-2018-16, MRCG-2018-16)
National Health and Medical Research Council (APP1183640, APP1183640, APP1183640)
H2020 Marie Skłodowska-Curie Actions (TECNIOspring PLUS 712949)
Agency for Business Competitiveness of the Government of Catalonia (TECSPR18-1-0056)
Cystic Fibrosis Foundation (OGARA1710, STICK10K0, OGARA1710)
European Comission (EU-634486, EU-634486)
Science Foundation Ireland (SSPC-2/PharM5, SSPC-2/PharM5)
Enterprise Ireland Commercialisation Fund (CF-2017-0757-P, CF-2017-0757-P)
The Institute for Respiratory Health (Glenn Brown Memorial Grant 2017)
Article History
Received: 22 April 2022
Accepted: 5 April 2023
First Online: 13 June 2023
Declarations
:
: This ancillary study was part of the exploratory outcomes of the COMBAT CF study protocol. Site-specific hospital Human Research Ethics Committee approved the COMBAT-CF trial and informed consent was obtained from parents/guardians.
: Not applicable.
: The authors declare no competing interests